The Delgoffe lab is psyched to be attending and presenting at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting in National Harbor, MD!
Two of our lab members are giving talks at SITC 2017 on Friday in Concurrent Session 108: Energizing Immune Cell Metabolism in Cancer:
- Greg M. Delgoffe @ 5:45 – 6:05p - Metabolic Changes in Tumor Microenvironment
McLane (Mac) Watson @ 6:20 – 6:35p - Lactic Acid as a Mediator of Metabolic Symbiosis Between Regulatory T cells and the Tumor Microenvironment
Three additional lab members are presenting during the poster sessions:
- Ashley Menk - 4-1BB costimulation enables PD-1 blockade therapy by inducing T cell mitochondrial function and biogenesis - P152
- Dayana Rivadeneira - A novel metabolic therapeutic that harnesses the anti-tumor immune response - P484
- Nicole Scharping - Immunometabolic requirements for T cell exhaustion - P156
Come check out our research to learn more about T cell metabolism and immunotherapy in the tumor microenvironment!
Our lab is thrilled to to announce that we recently received two grants from the NIH:
- Greg Delgoffe received the NIH Director’s New Innovator Award for his grant entitled "Exploring and exploiting metabolic plasticity in regulator T cells".
- Graduate student Nicole Scharping received the National Cancer Institute Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) for her grant entitled "Tumor-infiltrating T cell metabolic dysfunction and genetic reprogramming for effective immunotherapy".
Lily Delgoffe joined our lab (and the world) on September 10th, 2017. A Pittsburgh local, Lily has the heart of a scientist: excited to explore the world and follow her curiosity. While she is new to benchwork, her excellent mentors Greg and Abby Delgoffe (aka Mom and Dad) are delighted to teach her the ropes. Welcome to the lab, Lily!
Hello internet! Long time, no post! While this blog may have been relegated to the bottom of the to-do list, our science has not - our lab has been busy at both bench and keyboard to both better understand T cell metabolism in the tumor microenvironment. We have had some exciting milestones in the past couple of months, which we will briefly highlight in this post.
Our fearless leader, Dr. Greg Delgoffe, has had the opportunity to share our work at a number of national and international conferences in the past couple of months. He presented “Overcoming metabolic checkpoints to antitumor immunity” at the 9th Cellular Therapy Symposium in Erlangen, Germany, and at the 4th ImmunoTherapy Of Cancer Conference in Prague, Czech Republic. Greg also presented work on T cell metabolism at the American Transplant Congress in Chicago, Illinois and at the Transplantation Science Seminar in Victoria, British Columbia. Congrats, Greg!
New lab members:
While a few lab members have moved on to bigger and better things, we would like to formally welcome Dr. Dayana Rivadeneira (postdoctoral fellow) and McLane (Mac) Watson (graduate student)! Welcome to the lab guys!
New social media:
We are live on Twitter! Follow us @DelgoffeLab for day to day updates on lab news and events. We sign our tweets by hashtagging our initials, so you can see who has been tweeting.
That’s all for now, but not for long!
We have many exciting events coming along the pipeline - stay tuned to this blog or follow us on Twitter for updates!
Immunotherapy is likely hampered by a metabolically restrictive tumor microenvironment. This week in Cancer Immunology Research, our paper went live describing a role for the type II diabetes drug metformin as a metabolic remodeling agent that enables effective immunotherapy in mouse models!
Happy to report that our Young Investigator Award, "Metabolic reprogramming of tumor-specific T cells for immunotherapy," was funded through the Alliance for Cancer Gene Therapy! This award supports research using genetic engineering to create superior, long-lived T cell for the treatment of murine cancer, and using that model to generate superior human T cells!
Thanks to the Stand Up To Cancer Innovative Research Program, we received funding to explore metabolic reprogramming using some really cutting-edge therapeutic tools: oncolytic viruses. While this was a pretty stressful grant process, we are thrilled to be a part of the SU2C team.